(E)-3-氨基-4,4-二甲氧基丁烯酸酯 | 85396-57-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (E)-3-氨基-4,4-二甲氧基丁烯酸酯
• 中文别名: (E)-3-氨基-4,4-二甲氧基丁烯酸甲酯
• 英文名称: methyl 3-amino-4,4-dimethoxy-2-butanoate
• 英文别名: methyl 4,4-dimethoxy-3-aminocrotonate；methyl 3-amino-4,4-dimethoxycrotonate；Methyl 3-amino-4,4-dimethoxybut-2-enoate；methyl 3-amino-4,4-dimethoxybut-2-enoate
• CAS: 85396-57-2
• 化学式: C₇H₁₃NO₄
• mdl: MFCD20542937
• 分子量: 175.185
• InChiKey: RGAHQPXNVPJMRO-UHFFFAOYSA-N

物化性质

• 沸点：
  95.6 °C(Press: 5 Torr)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-氨基-4,4-二甲氧基丁烯酸酯 在 盐酸 、 sodium tetrahydroborate 作用下， 以 甲醇 、 丙酮 、 乙腈 为溶剂， 反应 133.0h， 生成 methyl 2-hydroxymethyl-6-methyl-5-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(2-trifluoromethylphenyl)-1,4-dihydropyridine-3-carboxylate
  参考文献：
  名称：

  Syntheses and antihypertensive activities of 1,4-dihydropyridine-5-phosphonate derivatives. III.

  摘要：

  设计并合成了多种1-和2-取代以及1, 2-融合的1, 4-二氢吡啶-5-膦酸酯衍生物，作为1, 4-二氢吡啶-3, 5-二羧酸盐的类似物，研究了它们的抗高血压活性。几个化合物在降低正常血压和自发性高血压大鼠的血压方面证明与尼非地平相当或更优。在这些化合物中，1-取代的1, 4-二氢吡啶衍生物显示出强效的抗高血压活性。讨论了它们的结构-活性关系。

  DOI：

  10.1248/cpb.35.4819
• 作为产物：
  描述：

  4,4-二甲氧基乙酰乙酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 20.0h， 以85%的产率得到(E)-3-氨基-4,4-二甲氧基丁烯酸酯
  参考文献：
  名称：

  Syntheses and antihypertensive activities of 1,4-dihydropyridine-5-phosphonate derivatives. III.

  摘要：

  设计并合成了多种1-和2-取代以及1, 2-融合的1, 4-二氢吡啶-5-膦酸酯衍生物，作为1, 4-二氢吡啶-3, 5-二羧酸盐的类似物，研究了它们的抗高血压活性。几个化合物在降低正常血压和自发性高血压大鼠的血压方面证明与尼非地平相当或更优。在这些化合物中，1-取代的1, 4-二氢吡啶衍生物显示出强效的抗高血压活性。讨论了它们的结构-活性关系。

  DOI：

  10.1248/cpb.35.4819

文献信息

• Studies on Nilvadipine. III. Syntheses of Metabolites of Nilvadipine and Their Related Compounds.
  作者：Yoshinari SATOH、Kazuo OKUMURA、Youichi SHIOKAWA

  DOI：10.1248/cpb.40.1799

  日期：——

  Nilvadipine (I), isopropyl 2-cyano-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-5-carboxylate, has a unique 1, 4-dihydropyridine structure in that the substituents at all five positions of the nucleus differ from one another. It is an excellent calcium antagonist drug in terms of its potency, its duration of action and its selectivity in the blood vascular system.During the development of I, some metabolites were isolated from the urine and bile of both rats and dogs afteroral administration. With data obtained from the metabolism of known 1, 4-dihydropyridines at hand, we proposed the synthesis of a series of compounds (1-11) for comparison with the metabolites isolated from I as a method for structure determination. Indeed, of the compounds synthesized five of them (3-7) were found to coincide with the metabolites from both rat and dog urine and bile isolates.

  尼伐地平（I）是 2-氰基-3-甲氧羰基-6-甲基-4-(3-硝基苯基)-1, 4-二氢吡啶-5-羧酸异丙酯，具有独特的 1, 4-二氢吡啶结构，其核的五个位置上的取代基彼此不同。在 I 的研发过程中，从大鼠和狗口服后的尿液和胆汁中分离出了一些代谢物。根据已知 1，4-二氢吡啶的代谢数据，我们提议合成一系列化合物（1-11），与从 I 中分离出的代谢物进行比较，以此作为确定结构的方法。事实上，在合成的化合物中，我们发现其中五个（3-7）与从大鼠和狗的尿液和胆汁中分离出来的代谢物相吻合。
• Pyridazinone compound and pharmaceutical use thereof
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20040067955A1

  公开（公告）日：2004-04-08

  A pyridazinone or pyridone compound of the following formula (I). 1 wherein X is 2 Y is N or CH or a salt thereof. The pyridazinone or pyridone compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.

  以下是化学式（I）的吡啶并嗪酮或吡啶酮化合物： 其中，X为2，Y为N或CH，或其盐。 本发明的吡啶并嗪酮或吡啶酮化合物（I）及其盐是腺苷拮抗剂，可用于预防和/或治疗抑郁症、痴呆症（例如阿尔茨海默病、脑血管性痴呆、帕金森病相关的痴呆等）、帕金森病、焦虑症、疼痛、脑血管疾病（例如中风等）、心力衰竭等。
• 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0063747A1

  公开（公告）日：1982-11-03

  Novel compounds having vasodilation and hypotensive effects are represented by the formula where R' is halogen, nitro, cyano or lower alkoxy; each of R2 and R3 is lower alkyl, lower haloalkyl, lower alkoxyalkyl, aralkyloxyalkyl, aryloxyalkyl, lower alkenoxyalkyl, N,N-di-lower alkylaminoalkyl, N-lower alkyl-N-aralkylaminoalkyl, piperidylalkyl, 4-lower alkyl piperazinylalkyl, norpholinoalkyl or 1-pyrrolidinylalkyl; R' is lower alkyl; A is lower alkylene; and R5 is hydrogen, lower alkyl, cycloalkyl of 3 to 7 carbon atoms, or aryl unsubstituted or substituted by one or two substituents selected from halogen, nitro, lower alkyl, lower alkoxy, di-lower alkylamino and cyano. Also disclosed are processes for their preparation.

  具有血管扩张和降血压作用的新型化合物由式表示 其中 R'为卤素、硝基、氰基或低级烷氧基；R2 和 R3 分别为低级烷基、低级卤代烷基、低级烷氧基烷基、芳氧基烷基、芳氧基烷基、低级烯氧基烷基、N,N-二低级烷基氨基烷基、N-低级烷基-N-芳基氨基烷基、哌啶基烷基、4-低级烷基哌嗪基烷基、去甲酚基烷基或 1-吡咯烷基烷基；R' 是低级烷基；A 是低级亚烷基；R5 是氢、低级烷基、3 至 7 个碳原子的环烷基或未取代的芳基，或被选自卤素、硝基、低级烷基、低级烷氧基、二低级烷基氨基和氰基的一个或两个取代基取代的芳基。 还公开了其制备工艺。
• 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0127150A2

  公开（公告）日：1984-12-05

  A compound of the formula: in which R' is aryl which may have one or more suitable substituent(s) or a heterocyclic group, R' is an esterfied carboxy group, R3 is lower alkyl, acyl, protected acyl or cyano, R4 is lower alkyl and A is lower alkylene, and pharmaceutically acceptable salt thereof, processes for its preparation and pharmaceutical compositions, containing them in association with pharmaceutical carrier or diluent. The invention also relates to intermediates for preparing the above compounds.

  以下式子的化合物 其中 R' 为芳基，可带有一个或多个合适的取代基，或杂环基、 R' 是酯化羧基、 R3 是低级烷基、酰基、受保护酰基或氰基、 R4 是低级烷基 A 是低级亚烷基、 及其药学上可接受的盐、制备方法和药物组合物，其中含有与药物载体或稀释剂结合的这些物质。本发明还涉及制备上述化合物的中间体。
• Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
  申请人：FISONS plc

  公开号：EP0174131A2

  公开（公告）日：1986-03-12

  There are described compounds of formula 1, in which R,, R2, R3, Rs and R6 are as defined in the specification and R4 is a phenyl group carrying 3 or 4 substituents or is an unsaturated 5 membered heterocyclic group containing a single hetero-atom selected from oxygen, sulphur or nitrogen, R4 being substituted by CF3, XR22, nitro, halogen, CN, alkyl C1 to 6, formyl dioxalanyl, -N(R23)COR24 -CONR25R26, or amino which is optionally substituted by phenylsulphonyl or by trifluoroacetyl, and R4 carries a substituent on the atom adjacent to the atom through which R4 is connected to the remainder of the molecule, R22 is phenyl or alkyl C1 to 6 optionally substituted by halogen, X is 0 or S(O)n, n is 0, 1 or 2, and R23, R24, R25 and R26, which may be the same or different, are each hydrogen or alkyl C1 to 6. There are also described methods for making the compounds, and their formulation and use as pharmaceuticals, eg for the treatment of cardiovascular conditions. There are further described compounds R4CHO which are useful in making compounds of formula I.

  所述化合物为式 1、 其中 R,、R2、R3、Rs 和 R6 如说明书中所定义，R4 是带有 3 或 4 个取代基的苯基，或者是含有一个选自氧、硫或氮的杂原子的不饱和 5 位杂环基团，R4 被 CF3、XR22、R4被 、XR22、硝基、卤素、CN、C1-6 烷基、二噁烷甲酰基、-N(R23)COR24-CONR25R26 或任选被苯磺酰基或三氟乙酰基取代的氨基取代，且 R4 在与 R4 通过其与分子其余部分相连的原子相邻的原子上带有一个取代基、 R22 是苯基或任选被卤素取代的 C1 至 6 烷基、 X 是 0 或 S(O)n、 n 是 0、1 或 2，以及 R23、R24、R25 和 R26（可以相同或不同）各自为氢或 C1-6 烷基。 还描述了制造这些化合物的方法，以及它们作为药物的配制和使用，例如用于治疗心血管疾病。 此外，还描述了可用于制造式 I 化合物的 R4CHO 化合物。